Wrapping up 2023: A recap of top biotech moments of this year
Another area of significant biotech breakthrough in 2023 is the development of new weight-loss drugs called GLP-1 analogues – which mimic the ...
new weight-loss drugs
Another area of significant biotech breakthrough in 2023 is the development of <anchor>new weight-loss drugs</anchor> called GLP-1 analogues – which mimic the GLP-1 hormone that is released in the gut in response to eating. These drugs are moving beyond traditional appetite suppressants to target underlying metabolic pathways and hormonal imbalances associated with obesity. This shift represents a more nuanced understanding of obesity’s biological underpinnings and opens up new possibilities for effective treatment options​​.
New weight loss drugs: biotech's mission to end obesity
Search for:

Suggested Topics:

- Categories

Browse by resource or article category

## Resources

## Categories

- Sectors

Browse by sector

## Approaches

## Therapeutic areas

- Drug Development

Stay informed on the latest drug development updates

## R&D

## BD

## World biotech leaders

- More

Learn more about Labiotech

## Company

## Join Us



Search for:

## Top Topics

HomeIn DepthNew weight loss drugs: biotech’s mission to end obesity

# New weight loss drugs: biotech’s mission to end obesity

Willow Shah Neville

8 minutesmins

July 25, 2023-Updated:  onSeptember 11, 2024

8 minutesmins

Share

- [Share on Whatsapp  
  WhatsApp](https://wa.me/?text=New weight loss drugs: biotech’s mission to end obesity%20on%20Labiotech.eu%20https://www.labiotech.eu/in-depth/new-weight-loss-drugs/)
- [Share on Twitter  
  Twitter](https://twitter.com/intent/tweet/?text=New weight loss drugs: biotech’s mission to end obesity%20on%20Labiotech.eu&url=https://www.labiotech.eu/in-depth/new-weight-loss-drugs/)
- [Share on Linkedin  
  Linkedin](https://www.linkedin.com/shareArticle?mini=true&url=https://www.labiotech.eu/in-depth/new-weight-loss-drugs/&title=New weight loss drugs: biotech’s mission to end obesity%20on%20Labiotech.eu&summary=New weight loss drugs: biotech’s mission to end obesity%20on%20Labiotech.eu&source=https://www.labiotech.eu/in-depth/new-weight-loss-drugs/)
- [Email this  
  Email](mailto:?subject=New weight loss drugs: biotech’s mission to end obesity%20on%20Labiotech.eu&body=https://www.labiotech.eu/in-depth/new-weight-loss-drugs/)

Photo/Shutterstock

Obesity drug market

[Share on Whatsapp](https://wa.me/?text=New weight loss drugs: biotech’s mission to end obesity%20on%20Labiotech.eu%20https://www.labiotech.eu/in-depth/new-weight-loss-drugs/)[Share on Twitter](https://twitter.com/intent/tweet/?text=New weight loss drugs: biotech’s mission to end obesity%20on%20Labiotech.eu&url=https://www.labiotech.eu/in-depth/new-weight-loss-drugs/)[Share on Linkedin](https://www.linkedin.com/shareArticle?mini=true&url=https://www.labiotech.eu/in-depth/new-weight-loss-drugs/&title=New weight loss drugs: biotech’s mission to end obesity%20on%20Labiotech.eu&summary=New weight loss drugs: biotech’s mission to end obesity%20on%20Labiotech.eu&source=https://www.labiotech.eu/in-depth/new-weight-loss-drugs/)[Email this](mailto:?subject=New weight loss drugs: biotech’s mission to end obesity%20on%20Labiotech.eu&body=https://www.labiotech.eu/in-depth/new-weight-loss-drugs/)Visit us on Google News

Obesity has nearly tripled since 1975, becoming an ever-growing health threat. In 2016, it was estimated that more than 1.9 billion adults in the world were overweight, with more than 650 million of those being officially obese.

Obesity can be defined as abnormal or excessive fat accumulation that presents a risk to health, with a body mass index (BMI) of over 30 being the official indicator of whether an individual is obese or not.

And, according to statistics from the World Health Organization (WHO), more than four million people die every year as a result of being overweight or obese. This is because obesity is essentially a precursor to disease, potentially leading to type 2 diabetes, heart disease, and even some cancers.

Generally, the advice for overweight and obese people is to eat a healthy diet and do regular exercise, but the truth is that it is not quite as simple as that.

Hunger is controlled by powerful hormones and chemicals in the brain, and involves areas of the brain responsible for cravings and rewards. In many individuals with obesity, the hormones, and even the brain’s reward system, are dysfunctional, altering eating behavior and causing a strong physiological desire to eat more.

But, fortunately, this is where weight loss drugs come in; they can deal with the hormones related to obesity directly, which, in turn, can change behavior by regulating appetite and reducing cravings.

And, in recent times, obesity is finally being treated as the root cause of disease, leading to many biotech companies racing to develop new weight loss drugs that are more and more effective in reducing obesity, as well as having less side effects for the people taking them.

## New GLP-1 analogues: a breakthrough for obesity

GLP-1 analogues – which mimic the GLP-1 hormone that is released in the gut in response to eating – had originally been developed as a treatment for diabetes, but when one of the side effects of these medications was found to be weight loss, companies saw the promise and began to develop them as anti-obesity drugs as well.

This is thanks to the fact that GLP-1 analogues have several effects on individuals with obesity, including slowing down stomach emptying, reducing appetite by acting on the brain, and boosting the release of insulin, helping to regulate blood sugar levels.

Now, the newest GLP-1 analogue, semaglutide, is being viewed as a breakthrough as far as anti-obesity medication goes, after being approved by the U.S. Food and Drug Administration (FDA) in 2021 specifically for weight loss.

It was the first new weight loss drug – sold under the brand name Wegovy, as well as under Ozempic and Rybelsus for diabetes – to be approved since Saxenda in 2014, and happens to be much more effective in allowing people to lose weight.

In clinical trials, Wegovy was shown to reduce body weight in individuals with BMIs of 27 or greater by 15% over a period of 68 weeks and, on average, people lost around an eighth of that weight in the first month.

Wegovy is also given as a once-weekly injection at a dose of 2.4 milligrams, which is an improvement on earlier formulations like Saxenda, which needed to be given on a daily basis, causing a burden for patients.

## Glyscend Therapeutics announces positive topline phase 2a results for diabetes and obesity drug

Moving away from GLP-1s, there are also other types of weight loss drugs in development that work differently to currently approved drugs.

Glyscend Therapeutics is one company looking to develop a new generation of orally administered first-in-class gut-targeted polymer therapies, and is developing GLY-200 for the treatment of type 2 diabetes and obesity.

“Our lead compound, GLY-200, is designed to alter duodenal signaling by crosslinking to native intestinal mucin in a pH-dependent manner, enhancing its natural barrier properties. This enhanced mucus barrier results in a pharmacologic ‘duodenal exclusion’ that may non-invasively and safely reproduce many of the beneficial effects of metabolic surgery, while avoiding the complications associated with invasive surgeries and procedures,” explained Glyscend’s chief executive officer (CEO) Ashish Nimgaonkar.

In developing this treatment, the company wanted to address the need for non-invasive, scalable alternatives that could replicate the effectiveness of metabolic surgery, which is invasive, expensive, and can come with possible complications.

“Moreover, none of the currently available treatments are considered disease-modifying, except for metabolic surgery. It has immediate profound effects on improving blood glucose and weight loss, with longer term reductions in macro- and microvascular complications,” said Nimgaonkar.

It was recently announced that data across completed phase 1 and 2a trials demonstrated that the novel mechanism of GLY-200 offers significantly and clinically relevant reductions in postprandial glucose and body weight, supporting its advancement into a phase 2b trial.

## APH-012: Aphaia Pharma’s new weight loss drug candidate shows promise

Meanwhile, Aphaia Pharma is also developing a promising drug candidate for weight loss, APH-012, with a focus on why L-cells – nutrient-sensing cells in the distal part of the intestine – in patients with metabolic disease are largely deprived from contact with food, as this leads to a lack of endocrine, neuroendocrine, and neuronal stimulation, in turn promoting the progression of obesity.

“One reason is they have motility problems with their small intestines, so the passage of food is delayed, or is slowed down. They eat large quantities of food in a composition that has never been optimized, which actually means far too many proteins, far too many fats, and not enough carbohydrates, and not enough fibers on top of that,” explained Steffen-Sebastian Bolz, chief scientific officer (CSO) of Aphaia Pharma.

Another reason, he said, is the fact that the food we consume today – particularly in Western countries – is highly refined; we consume industrialized food whereby the different components, such as sugar, have been separated and then put back into a processed product.

“We knew we would need to formulate something that bypasses the food bolus independent of motility to get to the distal part of the intestine where nutrient-sensing cells are (L-cells). We designed something that behaves like a fluid, because fluid just falls down…and we had to decide what we wanted to bring down there,” said Bolz.

## Suggested Articles

## TIL therapies: the impact on cancer research

## How Personal Genomics Companies Are Changing Drug Development

## Re-coding the brain: Is CRISPR capable of curing neurodegenerative diseases?

## Could an Alzheimer’s vaccine make treatment more affordable?

## Genetic engineering giants: is China poised to lead the way?

“We developed small beads containing glucose that travel down and hit L-cells with a very low interpatient variability. And more or less at exactly 1.5 hours after ingestion, you see the increase in the key metabolic hormones GLP-1, glicentin, oxyntomodulin, etc. It’s very promising because we’re just emulating what nature has defined over millions of years. We did not re-invent anything.”

APH-012 is currently in phase 2 of clinical development; the study was initiated towards the end of 2022, and is expected to close in May next year.

## Decreasing side effects

Aphaia Pharma’s weight loss drug also appears to lead to very few side effects.

“We stimulate the release of GLP-1 and all the other hormones at concentrations that are comparable to a meal, and as such, we don’t expect side effects,” explained Bolz.

This is notable because, although the likes of Wegovy cause fewer side effects than previous GLP-1 analogues, such as Saxenda, they do still cause side effects that can be so difficult to put up with that it actually leads to people stopping the medication entirely.

“In terms of nausea, despite multiple steps of dose-titration to mitigate gastrointestinal (GI) side effects, moderate to severe nausea is often observed with the newer GLP-1 agonists that can lead to treatment discontinuation. The U.S. prescribing information for Wegovy and Mounjaro report 4.3% and 6.6% of subjects discontinued treatment due to gastrointestinal adverse reactions respectively in controlled clinical trials. Discontinuation in clinical practice is likely much higher,” commented Nimgaonkar.

Glyscend’s own drug candidate also appears to lead to less severe side effects than currently available weight loss drugs, with the number of patients reporting GI side effects in the phase 2 study decreasing over time during the two-week treatment period, and most reports of nausea were short-lived and resolved within a day.

“While a direct head-to-head study of GLY-200 compared to other weight loss drugs like Wegovy has not been completed and historical comparisons of GI side effects across studies have limitations, early studies suggest that GLY-200 GI side effects may be less severe than most other obesity drugs recently approved or in development,” Nimgaonkar said.

## Growing market for weight loss drugs

As obesity becomes more prevalent in the general population, the weight loss drug market grows with it.

In fact, with more and more biotech companies looking to develop new weight loss drugs, it is estimated that the global obesity therapeutic market could be worth $100 billion by around 2030, if not more.

“Obesity is a real disease with both near- and long-term clinical and psychosocial consequences to the individual. We therefore believe strongly that these patients should have access to effective therapies that are easy to administer and affordable,” said Nimgaonkar.

inpart logo

New technologies related to weight loss:

## Newsletter Signup - Under Article / In Page

"*" indicates required fields

## Subscribe to our newsletter to get the latest biotech news!

Name*

First NameLast Name

Job title*

Company name*

Email*

Consent*

I consent to share my personal data with Labiotech UG

We're committed to your privacy. Labiotech uses the information you provide to us to send you updates about promotions, special offers from our partners, and news. You may unsubscribe from these communications at any time. We will not share or sell your personal information. For more information, check out our Privacy Policy.

CAPTCHA

Name

This field is for validation purposes and should be left unchanged.

Labiotech.eu

## Latest Articles

## Stealth mode biotech startups: Everything you need to know

## Targeting inflammation: A revolution in disease treatment

## New treatments being developed for schizophrenia

## Biotech R&D crunch: The impact of the Inflation Reduction Act and economic challenges

ADVERTISEMENT



## Suggested Articles

Longevity drugs for dogs

## The next leap in pet health: longevity drugs for dogs

Food Waste Bioenergy

## Transforming Food Waste into Bioenergy

Geographic atrophy treatment: Apellis' Syfovre vs. Astellas' Izervay.

## Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment

Food allergy immunotherapy

## Battling food allergies: emerging immunotherapies

danuglipron

## Danuglipron: Is Pfizer’s oral weight loss pill a contender in the obesity market?

## Latest Articles

Stealth mode biotech startups

## Stealth mode biotech startups: Everything you need to know



## Targeting inflammation: A revolution in disease treatment

Schizophrenia clinical trials

## New treatments being developed for schizophrenia

Inflation Reduction Act

## Biotech R&D crunch: The impact of the Inflation Reduction Act and economic challenges

### Subscribe to our newsletter to get the latest biotech news!

### Our Other Brands

## Newsletter Signup - Footer

"*" indicates required fields

## Subscribe to our newsletter to get the latest biotech news!

Name*

First NameLast Name

Job title*

Company name*

Email*

Consent*

I consent to share my personal data with Labiotech UG

CAPTCHA

Phone

This field is for validation purposes and should be left unchanged.

Made with -Labiotech UG, All Rights Reserved-